DEAV2002/0050 US NP

We claim:

1. (previously presented) A compound of the formula I,



I

wherein

R1 and R2 are each independently H, O-(C_1-C_6)-alkyl, CO-(C_1-C_6)-alkyl, COO-(C_1-C_6)-alkyl, (C_1-C_6)-alkylene-COOH, (C_1-C_6)-alkylene-COO-(C_1-C_6)-alkyl or (C_1-C_6)-alkyl, wherein said (C_1-C_6)-alkyl is optionally substituted by OH, O-(C_1-C_4)-alkyl, NH_2, NH(C_1-C_4)-alkyl or N[(C_1-C_6)-alkyl]$_2$;

R3 and R4 are each independently F, Cl, Br, OH, NO_2, CN, (C_1-C_6)-alkyl, O-(C_1-C_4)-alkyl, O-(C_2-C_6)-alkenyl or (C_2-C_6)-alkynyl, wherein said (C_1-C_6)-alkyl, O-(C_1-C_4)-alkyl, O-(C_2-C_6)-alkenyl and (C_2-C_6)-alkynyl are optionally mono- or polysubstituted by F, Cl or Br;

R5 is H, F, Cl, Br, OH, NO_2, CN, (C_1-C_6)-alkyl, O-(C_1-C_4)-alkyl, CO-(C_1-C_6)-alkyl, (C_0-C_6)-alkylene-COOH, (C_0-C_6)-alkylene-COO-(C_1-C_6)-alkyl, SO_2-(C_1-C_6)-alkyl, O-(C_2-C_6)-alkenyl or (C_2-C_6)-alkynyl, wherein said (C_1-C_6)-alkyl, O-(C_1-C_4)-alkyl, CO-(C_1-C_6)-alkyl, (C_0-C_6)-alkylene-COOH, (C_0-C_6)-alkylene-COO-(C_1-C_6)-alkyl, SO_2-(C_1-C_6)-alkyl, O-(C_2-C_6)-alkenyl and (C_2-C_6)-alkynyl are optionally mono- or polysubstituted by F, Cl or Br;

DEAV2002/0050 US NP

A is H, F, Cl, Br, OH, NO_2, CN, (C_1-C_6)-alkyl, CO-(C_1-C_6)-alkyl, (C_1-C_6)-alkylene-COOH, (C_1-C_6)-alkylene-COO(C_1-C_6)-alkyl, SO_2-(C_1-C_6)-alkyl, (C_2-C_6)-alkenyl, (C_2-C_6)-alkynyl, O-(C_1-C_6)-alkyl, $S(O)_{1-2}$-(C_1-C_6)-alkyl-, NH-(C_1-C_6)-alkyl, N-$[(C_1-C_6)$-alkyl$]_2$, COO-(C_1-C_6)-alkyl, $CONH_2$, CONH-(C_1-C_6)-alkyl, CON-$[(C_1-C_6)$-alkyl$]_2$, SO_2NH_2, SO_2NH-(C_1-C_6)-alkyl, SO_2N-$[(C_1-C_6)$-alkyl$]_2$ or NHCOR6, wherein said (C_1-C_6)-alkyl, CO-(C_1-C_6)-alkyl, (C_1-C_6)-alkylene-COOH, (C_1-C_6)-alkylene-COO(C_1-C_6)-alkyl, SO_2-(C_1-C_6)-alkyl, (C_2-C_6)-alkenyl, (C_2-C_6)-alkynyl, O-(C_1-C_6)-alkyl, $S(O)_{1-2}$-(C_1-C_6)-alkyl-, NH-(C_1-C_6)-alkyl, N-$[(C_1-C_6)$-alkyl$]_2$, COO-(C_1-C_6)-alkyl, CONH-(C_1-C_6)-alkyl, CON-$[(C_1-C_6)$-alkyl$]_2$, SO_2NH-(C_1-C_6)-alkyl and SO_2N-$[(C_1-C_6)$-alkyl$]_2$ are optionally mono- or polysubstituted by F, Cl, Br, COOH, COO-(C_1-C_6)-alkyl, $CONH_2$, CONH-(C_1-C_6)-alkyl, CON$[(C_1-C_6)$-alkyl$]_2$ or OCO-(C_1-C_6)-alkyl;

R6 is H, (C_1-C_6)-alkyl, (C_3-C_7)-cycloalkyl, (C_3-C_7)-cycloalkyl-(C_1-C_4)-alkylene, (C_2-C_6)-alkenyl, (C_2-C_6)-alkynyl, (C_1-C_6)-alkylene-COO-(C_1-C_6)-alkyl, (C_1-C_6)-alkylene-CO-(C_1-C_6)-alkyl, (C_0-C_6)-alkylene-COOH, (C_1-C_6)-alkylene-$CONH_2$, (C_6-C_{10})-aryl, (C_1-C_4)-alkylene-(C_6-C_{10})-aryl, heteroaryl, (C_1-C_4)-alkylene-heteroaryl or CO-heteroaryl, wherein said (C_1-C_6)-alkyl, (C_3-C_7)-cycloalkyl, (C_3-C_7)-cycloalkyl-(C_1-C_4)-alkylene, (C_2-C_6)-alkenyl, (C_2-C_6)-alkynyl, (C_1-C_6)-alkylene-COO-(C_1-C_6)-alkyl, (C_1-C_6)-alkylene-CO-(C_1-C_6)-alkyl, (C_0-C_6)-alkylene-COOH and (C_1-C_6)-alkylene-$CONH_2$ are optionally mono- or polysubstituted by F, Cl, Br, O$(C_1-C_4$-alkyl), COO-$(C_1-C_4$-alkyl) or N-$[(C_1-C_4)$-alkyl$]_2$ and said (C_6-C_{10})-aryl, (C_1-C_4)-alkylene-(C_6-C_{10})-aryl, heteroaryl, (C_1-C_4)-alkylene-heteroaryl and CO-heteroaryl are optionally mono- or polysubstituted by F, Cl, Br, NO_2, CN, O-$(C_1-C_4$-alkyl), S-COO$(C_1-C_4$-alkyl), COO-$(C_1-C_4$-alkyl), N-$[(C_1-C_4)$-alkyl$]_2$ or (C_1-C_6)-alkyl;

n is 0, 1, 2 or 3;

m is 1, 2, 3, 4 or 5;

o is 0, 1, 2 or 3;

Het is a heterocyclic 4- to 7-membered ring which may contain up to four N, O or S heteroatoms and wherein said heterocyclic 4- to 7-membered ring is optionally substituted by R7, R8 and R9, with the proviso that said heterocyclic 4- to 7- membered ring cannot be pyrrole; and

R7, R8, and R9 are each independently H, F, Cl, Br, (C_1-C_6)-alkyl, O-(C_1-C_6)-alkyl, O-(C_2-C_6)-alkenyl, O-(C_2-C_6)-alkynyl, OH, oxo, O-(C_1-C_6)-alkyl, NH_2, NH-(C_1-C_6)-alkyl, N-$[(C_1-C_6)$-alkyl$]_2$, COOH, CO-(C_1-C_6)-alkyl, COO-(C_1-C_6)-alkyl, $CONH_2$, CONH-(C_1-C_6)-alkyl, CON-$[(C_1-C_6)$-alkyl$]_2$, (C_0-C_6)-alkylene-aryl or (C_1-C_6)-alkylene-COO-(C_1-C_6)-alkyl, wherein said (C_1-C_6)-alkyl, O-(C_1-C_6)-alkyl, O-(C_2-C_6)-alkenyl, O-(C_2-C_6)-alkynyl, O-(C_1-C_6)-alkyl, NH-(C_1-C_6)-alkyl, N-$[(C_1-C_6)$-alkyl$]_2$, CO-(C_1-C_6)-alkyl, COO-(C_1-C_6)-alkyl, CONH-(C_1-C_6)-alkyl, CON-$[(C_1-C_6)$-alkyl$]_2$, (C_0-C_6)-alkylene-aryl and (C_1-C_6)-alkylene-COO-(C_1-C_6)-alkyl are optionally substituted by COOH, $CONH_2$, CONH-(C_1-C_6)-alkyl, CON-$[(C_1-C_6)$-alkyl$]_2$, OCO-(C_1-C_6)-alkyl, F, Cl, (C_1-C_6)-alkyl or O-(C_1-C_6)-alkyl; and two radicals selected from said R7, R8 and R9 may optionally be bonded together to form a ring fused onto said heterocyclic 4- to 7-membered ring;

and pharmaceutically acceptable salts thereof.

2. (previously presented) The compound of Claim 1 wherein

R1 and R2 are H;

R3 and R4 are each independently F, Cl or Br;

R5 is H, F, Cl, Br, OH, NO_2, CN, (C_1-C_6)-alkyl, O-(C_1-C_4)-alkyl, CO-(C_1-C_6)-alkyl, (C_0-C_6)-alkylene-COOH, (C_0-C_6)-alkylene-COO-(C_1-C_6)-alkyl, SO_2-(C_1-C_6)-alkyl, O-(C_2-C_6)-alkenyl or (C_2-C_6)-alkynyl, wherein said (C_1-C_6)-alkyl, O-(C_1-C_4)-alkyl, CO-(C_1-C_6)-alkyl, (C_0-C_6)-alkylene-COOH, (C_0-C_6)-alkylene-COO-(C_1-C_6)-alkyl, SO_2-(C_1-C_6)-alkyl, O-(C_2-C_6)-alkenyl and (C_2-C_6)-alkynyl are optionally mono- or polysubstituted by F, Cl or Br;

A is H, F, Cl, Br, OH, NO_2, CN, (C_1-C_6)-alkyl, CO-(C_1-C_6)-alkyl, (C_1-C_6)-alkylene-COOH, (C_1-C_6)-alkylene-COO(C_1-C_6)-alkyl, SO_2-(C_1-C_6)-alkyl, (C_2-C_6)-alkenyl, (C_2-C_6)-alkynyl, O-(C_1-C_6)-alkyl, $S(O)_{1-2}$-(C_1-C_6)-alkyl-, NH-(C_1-C_6)-alkyl, N-$[(C_1-C_6)$-alkyl$]_2$, COO-(C_1-C_6)-alkyl, $CONH_2$, CONH-(C_1-C_6)-alkyl, CON-$[(C_1-C_6)$-alkyl$]_2$, SO_2NH_2, SO_2NH-(C_1-C_6)-alkyl, SO_2N-$[(C_1-C_6)$-alkyl$]_2$ or NHCOR6, wherein said (C_1-C_6)-alkyl, CO-(C_1-C_6)-alkyl, (C_1-C_6)-alkylene-COOH, (C_1-C_6)-alkylene-COO(C_1-C_6)-alkyl, SO_2-(C_1-C_6)-alkyl, (C_2-C_6)-alkenyl, (C_2-C_6)-alkynyl, O-(C_1-C_6)-alkyl, $S(O)_{1-2}$-(C_1-C_6)-alkyl-, NH-(C_1-C_6)-alkyl, N-$[(C_1-C_6)$-alkyl$]_2$, COO-(C_1-C_6)-alkyl, CONH-(C_1-C_6)-alkyl, CON-$[(C_1-C_6)$-alkyl$]_2$, SO_2NH-(C_1-C_6)-alkyl and SO_2N-$[(C_1-C_6)$-alkyl$]_2$ are optionally mono- or polysubstituted by F, Cl, Br, COOH, COO-(C_1-C_6)-alkyl, $CONH_2$, CONH-(C_1-C_6)-alkyl, CON-$[(C_1-C_6)$-alkyl$]_2$ or OCO-(C_1-C_6)-alkyl;

R6 is H, (C_1-C_6)-alkyl, (C_3-C_7)-cycloalkyl, (C_3-C_7)-cycloalkyl-(C_1-C_4)-alkylene, (C_2-C_6)-alkenyl, (C_2-C_6)-alkynyl, (C_1-C_6)-alkylene-COO-(C_1-C_6)-alkyl, (C_1-C_6)-alkylene-CO-(C_1-C_6)-alkyl, (C_0-C_6)-alkylene-COOH, (C_1-C_6)-alkylene-$CONH_2$, (C_6-C_{10})-aryl, (C_1-C_4)-alkylene-(C_6-C_{10})-aryl, heteroaryl, (C_1-C_4)-alkylene-heteroaryl or CO-heteroaryl, wherein said (C_1-C_6)-alkyl, (C_3-C_7)-cycloalkyl, (C_3-C_7)-cycloalkyl-(C_1-C_4)-alkylene, (C_2-C_6)-alkenyl, (C_2-C_6)-alkynyl, (C_1-C_6)-alkylene-COO-(C_1-C_6)-alkyl, (C_1-C_6)-alkylene-CO-(C_1-C_6)-alkyl, (C_0-C_6)-alkylene-COOH and (C_1-C_6)-

alkylene-$CONH_2$ are optionally mono- or polysubstituted by F, Cl, Br, O-$(C_1$-$C_4)$-alkyl, COO-$(C_1$-C_4-alkyl), or N-$[(C_1$-$C_4)$-alkyl$]_2$, and said $(C_6$-$C_{10})$-aryl, $(C_1$-$C_4)$-alkylene-$(C_6$-$C_{10})$-aryl, heteroaryl, $(C_1$-$C_4)$-alkylene-heteroaryl and CO-heteroaryl are optionally mono- or polysubstituted by F, Cl, Br, NO_2, CN, O-$(C_1$-C_4-alkyl), COO-$(C_1$-C_4-alkyl), S-COO$(C_1$-C_4-alkyl), N-$[(C_1$-$C_4)$-alkyl$]_2$ or $(C_1$-$C_6)$-alkyl;

n is 0, 1 or 2;

m is 1;

o is 0 or 1;

Het is a heterocyclic 4- to 7-membered ring selected from triazolyl, tetrazolyl, oxadiazolyl, pyrazolyl, benzimidazolyl; furyl, triazinyl or



wherein said heterocyclic 4- to 7-membered ring is optionally substituted by R7, R8 and R9; and

R7, R8, and R9 are each independently H, F, Cl, Br, $(C_1$-$C_6)$-alkyl , O-$(C_1$-$C_6)$-alkyl, O-$(C_2$-$C_6)$-alkenyl, O-$(C_2$-$C_6)$-alkynyl, OH, oxo, O-$(C_1$-$C_6)$-alkyl, NH_2, NH-$(C_1$-$C_6)$-alkyl, N-$[(C_1$-$C_6)$-alkyl$]_2$, COOH, CO-$(C_1$-$C_6)$-alkyl, COO-$(C_1$-$C_6)$-alkyl, $CONH_2$, CONH-$(C_1$-$C_6)$-alkyl, CON-$[(C_1$-$C_6)$-alkyl$]_2$, $(C_0$-$C_6)$-alkylene-aryl or $(C_1$-$C_6)$-alkylene-COO-$(C_1$-$C_6)$-alkyl, wherein said $(C_1$-$C_6)$-alkyl , O-$(C_1$-$C_6)$-alkyl, O-$(C_2$-$C_6)$-alkenyl, O-$(C_2$-$C_6)$-alkynyl, O-$(C_1$-$C_6)$-alkyl, NH-$(C_1$-$C_6)$-alkyl, N-$[(C_1$-$C_6)$-alkyl$]_2$, CO-$(C_1$-$C_6)$-alkyl, COO-$(C_1$-$C_6)$-alkyl, CONH-$(C_1$-$C_6)$-alkyl, CON-$[(C_1$-$C_6)$-alkyl$]_2$, $(C_0$-$C_6)$-alkylene-aryl and $(C_1$-$C_6)$-alkylene-COO-$(C_1$-$C_6)$-alkyl are optionally substituted by COOH, $CONH_2$, CONH-$(C_1$-$C_6)$-alkyl, CON-$[(C_1$-$C_6)$-alkyl$]_2$, OCO-$(C_1$-$C_6)$-alkyl, F, Cl, $(C_1$-$C_6)$-alkyl or O-$(C_1$-$C_6)$-alkyl;

and two radicals selected from said R7, R8 and R9 may optionally be bonded together to form a ring fused onto said heterocyclic 4- to 7-membered ring;

and pharmaceutically acceptable salts thereof.

3. (previously presented) The compound of Claim 2 wherein

R1 and R2 are H;

R3 and R4 are each independently F, Cl or Br;

R5 is H, F, Cl, Br, OH, NO_2, CN, $(C_1$-$C_6)$-alkyl, O-$(C_1$-$C_4)$-alkyl, CO-$(C_1$-$C_6)$-alkyl, $(C_0$-$C_6)$-alkylene-COOH, $(C_0$-$C_6)$-alkylene-COO-$(C_1$-$C_6)$-alkyl, SO_2-$(C_1$-$C_6)$-alkyl, O-$(C_2$-$C_6)$-alkenyl or $(C_2$-$C_6)$-alkynyl, wherein said $(C_1$-$C_6)$-alkyl, O-$(C_1$-$C_4)$-alkyl, CO-$(C_1$-$C_6)$-alkyl, $(C_0$-$C_6)$-alkylene-COOH, $(C_0$-$C_6)$-alkylene-COO-$(C_1$-$C_6)$-alkyl, SO_2-$(C_1$-$C_6)$-alkyl, O-$(C_2$-$C_6)$-alkenyl and $(C_2$-$C_6)$-alkynyl are optionally mono- or polysubstituted by F, Cl or Br;

A is H, F, Cl, Br, $(C_1$-$C_6)$-alkyl, CF_3, OCF_3, NO_2, CN, O-$(C_1$-$C_6)$-alkyl, CO-$(C_1$-$C_6)$-alkyl, $(C_1$-$C_6)$-alkylene-COOH, $(C_1$-$C_6)$-alkylene-COO-$(C_1$-$C_6)$-alkyl, COO-$(C_1$-$C_6)$-alkyl or SO_2-$(C_1$-$C_6)$-alkyl;

n is 0, 1 or 2;

m is 1;

o is 0 or 1;

Het is a heterocyclic 4- to 7-membered ring group selected from triazolyl, tetrazolyl, oxadiazolyl, furyl, triazinyl or  , wherein said 4- to 7-membered heterocyclic ring is optionally substituted by R7, R8 and R9; and

R7, R8, and R9 are each independently H, $(C_1\text{-}C_6)$-alkyl, OH, oxo, NH_2, COOH, COO-$(C_1\text{-}C_6)$-alkyl, $CONH_2$, CONH-$(C_1\text{-}C_6)$-alkyl or CON-$[(C_1\text{-}C_6)\text{-alkyl}]_2$, wherein said $(C_1\text{-}C_6)$-alkyl, COO-$(C_1\text{-}C_6)$-alkyl, CONH-$(C_1\text{-}C_6)$-alkyl and CON-$[(C_1\text{-}C_6)\text{-alkyl}]_2$ are optionally substituted by COOH;

and pharmaceutically acceptable salts thereof.

4. (currently amended) The compound of Claim 1 wherein the compound has the structure Ia



Ia

wherein

R5 is H, F, Cl, Br, $(C_1\text{-}C_6)$-alkyl, CF_3, OCF_3, NO_2, CN, O-$(C_1\text{-}C_6)$-alkyl, CO-$(C_1\text{-}C_6)$-alkyl, $(C_0\text{-}C_6)$-alkylene-COOH, $(C_0\text{-}C_6)$-alkylene-COO-$(C_1\text{-}C_6)$-alkyl or SO_2-$(C_1\text{-}C_6)$-alkyl;

DEAV2002/0050 US NP

A is H, F, Cl, Br, (C_1-C_6)-alkyl, CF_3, OCF_3, NO_2, CN, O-(C_1-C_6)-alkyl, CO-(C_1-C_6)-alkyl, (C_1-C_6)-alkylene-COOH, (C_1-C_6)-alkylene–COO-(C_1-C_6)-alkyl, COO-(C_1-C_6)-alkyl or SO_2-(C_1-C_6)-alkyl;

R7 is H, (C_1-C_6)-alkyl, (C_0-C_6)-alkylene-aryl, O-(C_1-C_6)-alkyl, O-(C_2-C_6)-alkenyl or O-(C_2-C_6)-alkynyl, wherein said (C_1-C_6)-alkyl, (C_0-C_6)-alkylene-aryl, O-(C_1-C_6)-alkyl, O-(C_2-C_6)-alkenyl and O-(C_2-C_6)-alkynyl are optionally mono- or polysubstituted by F, Cl or Br;

R8 is -(C=O)-X;

X is OH, O-(C_1-C_6)-alkyl, NH_2, NH-(C_1-C_6)-alkyl or N-$((C_1-C_6)$-alkyl$)_2$; and

~~m is 1 or 2; and~~

n is 1 or 2;

and pharmaceutically acceptable salts thereof.

5. (previously presented) The compound of Claim 1 wherein the compound has the structure Iaa



Iaa

wherein

R5 is H or F;

A is H, F, Cl, (C_1-C_6)-alkyl, CF_3, COO-(C_1-C_6)-alkyl, or SO_2-(C_1-C_6)-alkyl;

R7 is H or phenyl;

R8 is -(C=O)-X; and

X is OH, O-(C_1-C_6)-alkyl, NH_2, NH-(C_1-C_6)-alkyl or N-$[(C_1-C_6)$-alkyl$]_2$;

and pharmaceutically acceptable salts thereof.

6. (original) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and one or more compounds of Claim 1.

7. (previously presented) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and one or more compounds of Claim 1 and at least one further active ingredient.

8. (withdrawn) The pharmaceutical composition of Claim 7, wherein said further active ingredient is selected from the group consisting of:
antidiabetics, hypoglycemic active ingredients, HMG-CoA reductase inhibitors, cholesterol absorption inhibitors, PPAR gamma agonists, PPAR alpha agonists, PPAR alpha/gamma agonists, fibrates, MTP inhibitors, bile acid absorption inhibitors, CETP inhibitors, polymeric bile acid adsorbents, LDL receptor inducers, ACAT inhibitors, antioxidants, lipoprotein lipase inhibitors, ATP-citrate-lyase inhibitors, squalene synthetase inhibitors, lipoprotein(a) antagonists, lipase inhibitors, insulins, sulfonylureas, biguanides, meglitinides, thiazolidinediones, α-glucosidase inhibitors, active ingredients acting on the ATP-dependent potassium channel of the beta cells, CART agonists, NPY

agonists, MC4 agonists, orexin agonists, H3 agonists, TNF agonists, CRF agonists, CRF BP antagonists, urocortin agonists, β3 agonists, MSH (melanocyte-stimulating hormone) agonists, CCK agonists, serotonin reuptake inhibitors, mixed serotoninergic and noradrenergic compounds, 5HT agonists, bombesin agonists, galanin antagonists, growth hormones, growth hormone-releasing compounds, TRH agonists, uncoupling protein 2 or 3 modulators, leptin agonists, DA agonists (bromocriptine, Doprexin), lipase/amylase inhibitors, PPAR modulators, RXR modulators or TR-β agonists or amphetamines.

9. (original) A method of reducing blood sugar comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Claim 1.

10. (original) A method for treating lipid and carbohydrate metabolism disorders comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Claim 1.

11. (original) A method for treating type 2 diabetes comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Claim 1.

12. (original) A method for treating arteriosclerotic symptoms comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Claim 1.

13. (original) A method for treating insulin resistance comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Claim 1.

14. (previously presented) A process for preparing a compound of Claim 1, which comprises reacting a urea of formula 2 with a compound of formula 4

DEAV2002/0050 US NP



2



4

wherein

R1 and R2 are each independently H, O-(C_1-C_6)-alkyl, CO-(C_1-C_6)-alkyl, COO-(C_1-C_6)-alkyl, (C_1-C_6)-alkylene-COOH, (C_1-C_6)-alkylene-COO-(C_1-C_6)-alkyl or (C_1-C_6)-alkyl, wherein said (C_1-C_6)-alkyl is optionally substituted by OH, O-(C_1-C_4)-alkyl, NH_2, NH(C_1-C_4)-alkyl or N[(C_1-C_6)-alkyl]$_2$;

R3 and R4 are each independently F, Cl, Br, OH, NO_2, CN, (C_1-C_6)-alkyl, O-(C_1-C_4)-alkyl, O-(C_2-C_6)-alkenyl or (C_2-C_6)-alkynyl, wherein said (C_1-C_6)-alkyl, O-(C_1-C_4)-alkyl, O-(C_2-C_6)-alkenyl and (C_2-C_6)-alkynyl are optionally mono- or polysubstituted by F, Cl or Br;

R5 is H, F, Cl, Br, OH, NO_2, CN, (C_1-C_6)-alkyl, O-(C_1-C_4)-alkyl, CO-(C_1-C_6)-alkyl, (C_0-C_6)-alkylene-COOH, (C_0-C_6)-alkylene-COO-(C_1-C_6)-alkyl, SO_2-(C_1-C_6)-alkyl, O-(C_2-C_6)-alkenyl or (C_2-C_6)-alkynyl, wherein said (C_1-C_6)-alkyl, O-(C_1-C_4)-alkyl, CO-(C_1-C_6)-alkyl, (C_0-C_6)-alkylene-COOH, (C_0-C_6)-alkylene-COO-(C_1-C_6)-alkyl, SO_2-(C_1-C_6)-alkyl, O-(C_2-C_6)-alkenyl and (C_2-C_6)-alkynyl are optionally mono- or polysubstituted by F, Cl or Br;

A is H, F, Cl, Br, OH, NO_2, CN, (C_1-C_6)-alkyl, CO-(C_1-C_6)-alkyl, (C_1-C_6)-alkylene-COOH, (C_1-C_6)-alkylene-COO(C_1-C_6)-alkyl, SO_2-(C_1-C_6)-alkyl, (C_2-C_6)-alkenyl, (C_2-C_6)-alkynyl, O-(C_1-C_6)-alkyl, S(O)$_{1-2}$-(C_1-C_6)-alkyl-, NH-(C_1-C_6)-alkyl, N-[(C_1-C_6)-alkyl]$_2$, COO-(C_1-C_6)-alkyl, $CONH_2$, CONH-(C_1-C_6)-alkyl, CON-[(C_1-C_6)-alkyl]$_2$, SO_2NH_2, SO_2NH-(C_1-C_6)-

alkyl, SO_2N-[$(C_1$-$C_6)$-alkyl]$_2$ or NHCOR6, wherein said $(C_1$-$C_6)$-alkyl, CO-$(C_1$-$C_6)$-alkyl, $(C_1$-$C_6)$-alkylene-COOH, $(C_1$-$C_6)$-alkylene-COO$(C_1$-$C_6)$-alkyl, SO_2-$(C_1$-$C_6)$-alkyl, $(C_2$-$C_6)$-alkenyl, $(C_2$-$C_6)$-alkynyl, O-$(C_1$-$C_6)$-alkyl, S(O)$_{1\text{-}2}$-$(C_1$-$C_6)$-alkyl-, NH-$(C_1$-$C_6)$-alkyl, N-[$(C_1$-$C_6)$-alkyl]$_2$, COO-$(C_1$-$C_6)$-alkyl, CONH-$(C_1$-$C_6)$-alkyl, CON-[$(C_1$-$C_6)$-alkyl]$_2$, SO_2NH-$(C_1$-$C_6)$-alkyl and SO_2N-[$(C_1$-$C_6)$-alkyl]$_2$ are optionally mono- or polysubstituted by F, Cl, Br, COOH, COO-$(C_1$-$C_6)$-alkyl, $CONH_2$, CONH-$(C_1$-$C_6)$-alkyl, CON[$(C_1$-$C_6)$-alkyl]$_2$ or OCO-$(C_1$-$C_6)$-alkyl;

n is 0, 1, 2 or 3;

R7 and R8 are each independently H, F, Cl, Br, $(C_1$-$C_6)$-alkyl, O-$(C_1$-$C_6)$-alkyl, O-$(C_2$-$C_6)$-alkenyl, O-$(C_2$-$C_6)$-alkynyl, OH, oxo, O-$(C_1$-$C_6)$-alkyl, NH_2, NH-$(C_1$-$C_6)$-alkyl, N-[$(C_1$-$C_6)$-alkyl]$_2$, COOH, CO-$(C_1$-$C_6)$-alkyl, COO-$(C_1$-$C_6)$-alkyl, $CONH_2$, CONH-$(C_1$-$C_6)$-alkyl, CON-[$(C_1$-$C_6)$-alkyl]$_2$, $(C_0$-$C_6)$-alkylene-aryl or $(C_1$-$C_6)$-alkylene-COO-$(C_1$-$C_6)$-alkyl, wherein said $(C_1$-$C_6)$-alkyl, O-$(C_1$-$C_6)$-alkyl, O-$(C_2$-$C_6)$-alkenyl, O-$(C_2$-$C_6)$-alkynyl, O-$(C_1$-$C_6)$-alkyl, NH-$(C_1$-$C_6)$-alkyl, N-[$(C_1$-$C_6)$-alkyl]$_2$, CO-$(C_1$-$C_6)$-alkyl, COO-$(C_1$-$C_6)$-alkyl, CONH-$(C_1$-$C_6)$-alkyl, CON-[$(C_1$-$C_6)$-alkyl]$_2$, $(C_0$-$C_6)$-alkylene-aryl and $(C_1$-$C_6)$-alkylene-COO-$(C_1$-$C_6)$-alkyl are optionally substituted by COOH, $CONH_2$, CONH-$(C_1$-$C_6)$-alkyl, CON-[$(C_1$-$C_6)$-alkyl]$_2$, OCO-$(C_1$-$C_6)$-alkyl, F, Cl, $(C_1$-$C_6)$-alkyl or O-$(C_1$-$C_6)$-alkyl; and said R7 and R8 may optionally be bonded together to form a ring fused onto said heterocyclic 4- to 7-membered ring; and

Y is Cl or



DEAV2002/0050 US NP

15. (previously presented) A process for preparing a compound of Claim 1, which comprises reacting an aniline derivative of formula 3 with a compound of formula 4



3



4

wherein

R2 is H, O-(C_1-C_6)-alkyl, CO-(C_1-C_6)-alkyl, COO-(C_1-C_6)-alkyl, (C_1-C_6)-alkylene-COOH, (C_1-C_6)-alkylene-COO-(C_1-C_6)-alkyl or (C_1-C_6)-alkyl, wherein said (C_1-C_6)-alkyl is optionally substituted by OH, O-(C_1-C_4)-alkyl, NH_2, NH(C_1-C_4)-alkyl or N[(C_1-C_6)-alkyl]$_2$;

R3 and R4 are each independently F, Cl, Br, OH, NO_2, CN, (C_1-C_6)-alkyl, O-(C_1-C_4)-alkyl, O-(C_2-C_6)-alkenyl or (C_2-C_6)-alkynyl, wherein said (C_1-C_6)-alkyl, O-(C_1-C_4)-alkyl, O-(C_2-C_6)-alkenyl and (C_2-C_6)-alkynyl are optionally mono- or polysubstituted by F, Cl or Br;

R5 is H, F, Cl, Br, OH, NO_2, CN, (C_1-C_6)-alkyl, O-(C_1-C_4)-alkyl, CO-(C_1-C_6)-alkyl, (C_0-C_6)-alkylene-COOH, (C_0-C_6)-alkylene-COO-(C_1-C_6)-alkyl, SO_2-(C_1-C_6)-alkyl, O-(C_2-C_6)-alkenyl or (C_2-C_6)-alkynyl, wherein said (C_1-C_6)-alkyl, O-(C_1-C_4)-alkyl, CO-(C_1-C_6)-alkyl, (C_0-C_6)-alkylene-COOH, (C_0-C_6)-alkylene-COO-(C_1-C_6)-alkyl, SO_2-(C_1-C_6)-alkyl, O-(C_2-C_6)-alkenyl and (C_2-C_6)-alkynyl are optionally mono- or polysubstituted by F, Cl or Br;

A is H, F, Cl, Br, OH, NO_2, CN, (C_1-C_6)-alkyl, CO-(C_1-C_6)-alkyl, (C_1-C_6)-alkylene-COOH, (C_1-C_6)-alkylene-COO(C_1-C_6)-alkyl, SO_2-(C_1-C_6)-alkyl,

$(C_2$-$C_6)$-alkenyl, $(C_2$-$C_6)$-alkynyl, O-$(C_1$-$C_6)$-alkyl, $S(O)_{1-2}$-$(C_1$-$C_6)$-alkyl-, NH-$(C_1$-$C_6)$-alkyl, N-$[(C_1$-$C_6)$-alkyl$]_2$, COO-$(C_1$-$C_6)$-alkyl, $CONH_2$, CONH-$(C_1$-$C_6)$-alkyl, CON-$[(C_1$-$C_6)$-alkyl$]_2$, SO_2NH_2, SO_2NH-$(C_1$-$C_6)$-alkyl, SO_2N-$[(C_1$-$C_6)$-alkyl$]_2$ or NHCOR6, wherein said $(C_1$-$C_6)$-alkyl, CO-$(C_1$-$C_6)$-alkyl, $(C_1$-$C_6)$-alkylene-COOH, $(C_1$-$C_6)$-alkylene-COO$(C_1$-$C_6)$-alkyl, SO_2-$(C_1$-$C_6)$-alkyl, $(C_2$-$C_6)$-alkenyl, $(C_2$-$C_6)$-alkynyl, O-$(C_1$-$C_6)$-alkyl, $S(O)_{1-2}$-$(C_1$-$C_6)$-alkyl-, NH-$(C_1$-$C_6)$-alkyl, N-$[(C_1$-$C_6)$-alkyl$]_2$, COO-$(C_1$-$C_6)$-alkyl, CONH-$(C_1$-$C_6)$-alkyl, CON-$[(C_1$-$C_6)$-alkyl$]_2$, SO_2NH-$(C_1$-$C_6)$-alkyl and SO_2N-$[(C_1$-$C_6)$-alkyl$]_2$ are optionally mono- or polysubstituted by F, Cl, Br, COOH, COO-$(C_1$-$C_6)$-alkyl, $CONH_2$, CONH-$(C_1$-$C_6)$-alkyl, CON$[(C_1$-$C_6)$-alkyl$]_2$ or OCO-$(C_1$-$C_6)$-alkyl;

n is 0, 1, 2 or 3;

R7 and R8 are each independently H, F, Cl, Br, $(C_1$-$C_6)$-alkyl, O-$(C_1$-$C_6)$-alkyl, O-$(C_2$-$C_6)$-alkenyl, O-$(C_2$-$C_6)$-alkynyl, OH, oxo, O-$(C_1$-$C_6)$-alkyl, NH_2, NH-$(C_1$-$C_6)$-alkyl, N-$[(C_1$-$C_6)$-alkyl$]_2$, COOH, CO-$(C_1$-$C_6)$-alkyl, COO-$(C_1$-$C_6)$-alkyl, $CONH_2$, CONH-$(C_1$-$C_6)$-alkyl, CON-$[(C_1$-$C_6)$-alkyl$]_2$, $(C_0$-$C_6)$-alkylene-aryl or $(C_1$-$C_6)$-alkylene-COO-$(C_1$-$C_6)$-alkyl, wherein said $(C_1$-$C_6)$-alkyl, O-$(C_1$-$C_6)$-alkyl, O-$(C_2$-$C_6)$-alkenyl, O-$(C_2$-$C_6)$-alkynyl, O-$(C_1$-$C_6)$-alkyl, NH-$(C_1$-$C_6)$-alkyl, N-$[(C_1$-$C_6)$-alkyl$]_2$, CO-$(C_1$-$C_6)$-alkyl, COO-$(C_1$-$C_6)$-alkyl, CONH-$(C_1$-$C_6)$-alkyl, CON-$[(C_1$-$C_6)$-alkyl$]_2$, $(C_0$-$C_6)$-alkylene-aryl and $(C_1$-$C_6)$-alkylene-COO-$(C_1$-$C_6)$-alkyl are optionally substituted by COOH, $CONH_2$, CONH-$(C_1$-$C_6)$-alkyl, CON-$[(C_1$-$C_6)$-alkyl$]_2$, OCO-$(C_1$-$C_6)$-alkyl, F, Cl, $(C_1$-$C_6)$-alkyl or O-$(C_1$-$C_6)$-alkyl; and said R7 and R8 may optionally be bonded together to form a ring fused onto said heterocyclic 4- to 7-membered ring; and

Y is –N=C=O.

16. (previously presented) A compound which is 1-{2-[3-(2-chloro-4,5-difluorobenzoyl)ureido]-4-fluorophenyl}piperidine-4-carboxylic acid and pharmaceutically acceptable salts thereof.